Amneal Pharmaceuticals announced it has received its first product approval in China. Sevelamer carbonate was approved and is expected to launch shortly. In addition, the company expects to launch oseltamivir phosphate in China this year as well, upon approval. In total, Amneal has six products pending review in China with more product registrations planned over time. Since 2019, the company has collaborated with Fosun Pharmaceuticals to bring key therapies to market in China.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMRX:
- Amneal says delegation of HHS, FDA members visited company facility in India
- Amneal Pharmaceuticals says RISE-PD study results published in JAMA Neurology
- Amneal Pharmaceuticals management to meet virtually with Piper Sandler
- Amneal Pharmaceuticals price target raised to $5 from $3 at Piper Sandler
- Amneal Pharmaceuticals price target raised to $5 from $4 at Barclays